Liyuan Chem

Liyuan (Shanghai) Biotechnology, also known as Liyuan Bio or Liyuan Chem, is a clinical-stage biopharmaceutical company and contract research organization (CRO) based in Shanghai, China. The company focuses on the discovery and development of innovative small molecule drugs, particularly for metabolic diseases such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Founded by industry veterans with experience at global pharmaceutical companies like Eli Lilly, Liyuan leverages a proprietary drug discovery platform to target G protein-coupled receptors (GPCRs) and nuclear receptors. Its lead clinical candidate, LY-001, is a GPR119 agonist designed to improve glycemic control and lipid metabolism. In addition to its internal pipeline, the company provides specialized medicinal chemistry and drug discovery services to global partners.